๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Varanasi
Clinical trial register · India

Clinical Trials in Varanasi

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
47 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Delhi, Kolkata, Mumbai, Pune, Varanasi
2024-10-18
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
NCT06561386Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
1,000
Badsa, Bengaluru, Thiruvananthapuram, Mumbai, New Delhi, Secunderabad, Varanasi, Howrah
2024-10-07
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Aurangabad, Nagpur, Chandigarh, Ajmer, Hyderabad, Kolkata, Varanasi
2024-09-26
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
AstraZeneca
Phase 3
620
Dehradun, Delhi, Kanpur, Kolkata, Mumbai, Vadodara, Varanasi
2024-08-12
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3
286
Belagavi, Mumbai, Nashik, Hyderabad, Varanasi, New Delhi
2024-07-19
Recruiting
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964Bipolar Depression
Intra-Cellular Therapies, Inc.
Phase 3
384
Ahmedabad, Aurangabad, Nashik, Varanasi
2024-05-14
Recruiting
Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy
NCT06926543Invasive Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer
Dr. Tabassum Wadasadawala
Phase 3
858
Vishkhapatnam, Mumbai, New Chandigarh, Sangrur, Varanasi
2024-05-14
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Delhi, Kolkata, Mumbai, Mysuru, New Delhi, Varanasi
2023-12-04
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
895
Bengaluru, Hyderabad, Kolkata, Mysuru, Nagpur, Varanasi
2023-10-24
Recruiting
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
NCT07062263Biliary Tract Cancer, HER2-positive Cancer, Advanced Cancer, Unresectable Biliary Tract Carcinoma
Tata Memorial Centre
Phase 3
220
Muzaffarpur, Mumbai, Bhubaneswar, Mลซllฤnpur, Varanasi, Delhi
2023-07-21
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Nagpur, Chandigarh, Ajmer, Hyderabad, Kolkata, Varanasi
2023-07-11
Active, closed
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression โ‰ฅ 1% and an STK11 Co-mutation.
NCT05445843Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression โ‰ฅ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals
Phase 2
95
Thellakom Kottayam, Varanasi
2022-12-06
Active, closed
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (โ‰ฅ18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Phase 3
568
Ahmedabad, New Delhi, Chennai, Varanasi, Rishikesh
2022-11-21
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
Celgene
Phase 3
810
Ahmedabad, Gurugram, Belagavi, Mumbai, Madurai, Varanasi, Ludhiana, Puducherry
2022-09-20
Active, closed
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05134441Multiple Sclerosis
Immunic AG
Phase 3
1,121
Bangalore, Mangalore, Nagpur, New Delhi, Pune, Shimla, Varanasi
2021-11-18
Recruiting
Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers
NCT04809324Oral Cavity Cancer
Dr.Pankaj Chaturvedi
Not applicable
1,206
Mumbai, Navi Mumbai, Varanasi
2021-11-15
Active, closed
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Phase 3
217
Kozhikode, Mumbai, New Delhi, Varanasi, Kolkata
2021-09-30
Active, closed
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
893
Bangalore, Mohali, Mysuru, Nagpur, New Delhi, Vadodara, Varanasi
2021-05-10
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
358
Mumbai, Namakkal, New Delhi, Varanasi
2020-12-16
Recruiting
NGS in Gallbladder Cancer and Response to Treatment
NCT05404347Gallbladder Cancer
Banaras Hindu University
Observational
100
Varanasi
2018-01-01
Recruiting
Newer Therapeutic Targets in Head and Neck Cancers
NCT05382585Head Neck Cancer, Oral Cancer
Banaras Hindu University
Observational
200
Varanasi
2017-04-01
Active, closed
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
NCT02932150Chronic Hepatitis B
Gilead Sciences
Phase 2
150
Kolkata, Lucknow, Mumbai, Nagpur, New Delhi, Surat, Varanasi
2016-11
Rows per page Showing 26–47 of 47
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/varanasi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.